Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis

Pooling 343 solid organ transplant recipients (most kidney) treated with immune checkpoint inhibitors for advanced cancer, this analysis found high rates of allograft rejection and cancer death, but lower rejection risk when mTOR inhibitors plus steroids were maintained.